ZYMEWORKS WKN: A3DSSN ISIN: US98985Y1082 Forum: Aktien User: Summer.76

⬆️

Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium https://www.businesswire.com/news/home/20221214005989/en/Zanidatamab-Clinical-Data-Selected-For-Presentation-At-The-American-Society-Of-Clinical-Oncology-ASCO-Gastrointestinal-Cancers-Symposium ...today announced the upcoming presentation of mature Phase 2 data evaluating zanidatamab in combination with chemotherapy as first-line treatment for HER2-positive gastroesophageal adenocarcinoma (GEA) at the ASCO Gastrointestinal Cancers Symposium, taking place in San Francisco, CA and virtually on January 19-21, 2023. ....

https://ir.zymeworks.com/news-releases/news-release-details/new-clinical-data-zanidatamab-her2-hr-metastatic-breast-cancer-0

...The company expects that its common stock (together with the associated preferred stock purchase rights) will cease trading on the NYSE at market close on December 15, 2022. The company expects its common stock (together with the associated preferred stock purchase rights) to commence trading on the Nasdaq on December 16, 2022, and will continue to be listed under the ticker symbol "ZYME".

https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-transfer-stock-listing-nasdaq Zymeworks To Transfer Stock Listing To Nasdaq

Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals https://www.businesswire.com/news/home/20221129005175/en/Zymeworks-Announces-Expiration-of-Hart-Scott-Rodino-Waiting-Period-for-Zanidatamab-License-Agreement-with-Jazz-Pharmaceuticals

https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-announces-participation-upcoming-investor-conference-0

Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Receptor Positive (HR+) Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS) https://www.businesswire.com/news/home/20221121005239/en/Zymeworks-Announces-Abstract-For-Zanidatamab-In-Late-Line-HER2-Positive-Hormone-Receptor-Positive-HR-Metastatic-Breast-Cancer-At-The-San-Antonio-Breast-Cancer-Symposium-SABCS ...A poster with an updated and expanded data set will be presented at SABCS taking place in San Antonio, Texas and virtually on December 6-9, 2022. ...

Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M https://seekingalpha.com/news/3904028-zymeworks-non-gaap-eps-of-0_66-beats-0_31-revenue-of-2_6m-misses-1_95m • Zymeworks press release (NYSE:ZYME): Q3 Non-GAAP EPS of -$0.66 beats by $0.31. • Revenue of $2.6M (-40.9% Y/Y) misses by $1.95M.

https://biv.com/article/2022/11/zymeworks-cuts-q3-losses-us48m-bc-biotech-reincorporates-us

Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results https://www.businesswire.com/news/home/20221108006218/en/Zymeworks-Provides-Corporate-Update-and-Reports-Third-Quarter-2022-Financial-Results

News fehlen, aber das Volumen ist ordentlich heute.